enGene Cuts Half Its Workforce as C-Suite Dissolves Before BLA
Distressed
Company Background
enGene Therapeutics is a clinical-stage gene therapy company whose pipeline is built around a single lead asset, detalimogene, currently being evaluated in the LEGEND pivotal trial. The company has no approved products and no product revenue; its path to commercial viability runs through regulatory approval of detalimogene. At approximately $115 million in market capitalization, enGene has limited financial cushion relative to the costs of late-stage drug development and the regulatory process ahead.
The twelve months prior to June 2026 produced no major catalysts or disclosed setbacks — the only notable corporate event was a routine Annual General Meeting on June 9, 2026, at which shareholders re-elected four directors, including CEO Ronald Cooper. There was no prior public signal of a restructuring.
What Was Disclosed
The board approved a roughly 50% workforce reduction on June 14, 2026, explicitly to "preserve shareholder capital as the Company awaits additional durability data and meetings with the Food and Drug Administration in connection with the Company's LEGEND pivotal cohort." Total estimated charges run from $10.4 million to $15.9 million: $5.7 million to $6.4 million in cash severance and benefits; $4.7 million to $5.0 million in non-cash expense from accelerated vesting of existing options; up to $1.7 million in cash performance retention awards; and up to $2.8 million in non-cash expense tied to new performance equity retention awards. The majority of these charges are expected to land in the second half of 2026.
The executive departures are extensive. CMO Dr. Hussein Sweiti resigned on June 13, effective June 14. CFO Ryan Daws departs July 15 and will receive 12 months of base salary continuation totaling $517,880, health insurance continuation, a prorated 2026 bonus, and acceleration of unvested time-based equity. CLO Lee Giguere and Chief Strategy and Operations Officer Alex Nichols also depart July 15. CSO Anthony Cheung exits September 30 but is expected to remain as a consultant for one year beginning October 1, 2026. To replace Sweiti, the board appointed sitting director Dr. William Grossman as Interim Chief Medical Officer effective June 15, working part-time at up to 15 hours per week. The board simultaneously dissolved its Research and Development Committee. Kathleen Richton, who has served as VP Controller since March 2026, was named SVP Finance and will succeed Daws as principal financial officer and principal accounting officer on or about July 16, at an annual base salary of $370,000.
On June 16, the Compensation Committee issued CEO Ronald Cooper a performance-based retention option covering 400,000 common shares at an exercise price of $1.75 per share — the closing price on the grant date. Half the options vest on FDA acceptance of a BLA for detalimogene, provided that acceptance arrives no later than September 30, 2027; the remaining half vest on FDA approval of detalimogene, provided that approval arrives no later than December 31, 2028. Continued employment is required at each vesting date. Four other executives — Chief Regulatory Officer Matthew Boyd, Chief Development Officer Jill Buck, Chief Technology Officer Joan Connolly, and Chief Global Commercialization Officer Amy Pott — received performance-based cash retention awards tied to the same BLA and approval milestones.
Why It Matters
The stated rationale — waiting for durability data and FDA meetings — means the timeline to BLA is not yet fixed and the company needed to extend its cash runway to stay in the game. The retention architecture confirms management's own view of how long that game may last: the outer vesting deadline for the CEO's options and the executives' retention awards runs to December 31, 2028, implying enGene is planning for a regulatory process that could stretch more than two years from today.
The simultaneous loss of the CMO, CFO, CLO, and Chief Strategy Officer — with the CSO moving to consulting — strips out most of the senior leadership at the moment the company says it is planning BLA initiation in the second half of 2026. The Interim CMO arrangement is unconventional: Dr. Grossman is a board member rather than a practicing drug developer, and his engagement is capped at 15 hours per week. While the company has stated it retained the personnel necessary to complete LEGEND Cohort 1, enroll the detalimogene-plus-surfactant cohort, and conduct pre-commercial activities for a potential 2027 launch, the depth of oversight available during the pivotal trial's final stages is now materially thinner.
The company has retained four C-suite officers tied to regulatory, development, technology, and commercial functions — the roles most directly linked to getting a BLA filed and commercialized. That selective retention, alongside the milestone-based structure of every new incentive award, suggests the remaining leadership has been organized around a single objective: getting detalimogene to approval or a transaction, whichever comes first.
